Shashikant Srivastava

Educator, Researcher

[Shashikant Srivastava @skant_uthct]

Almost time to witness the best game ever. Go Messi.

[Shashikant Srivastava @skant_uthct]

@SkylarSkye3 Really?

[Shashikant Srivastava @skant_uthct]

Saliva-based therapeutic drug monitoring could improve MDR-TB treatment outcomes, while reducing the risk of sub-therapeutic drug exposure and toxicity, if the patient achieves higher than the target exposure with the given drug dose https://t.co/wADOUhGQfy

[Shashikant Srivastava @skant_uthct]

New inhaled doses of imipenem, tigecycline, cefoxitin, and amikacin for Mycobacterium abscessus lung disease.

Systematic and quantitative analyses of hollow fiber model of Mycobacterium abscessus lung disease studies and new dosing recommendations https://t.co/J4HudKksVv

[Shashikant Srivastava @skant_uthct]

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease | Antimicrobial Agents and Chemotherapy https://t.co/vFignmswc0

[Shashikant Srivastava @skant_uthct]

The current recommended dose for isoniazid in children is appropriate, but future studies are needed to better understand potential need for adjusting the dose for specific subgroups displaying lower drug exposure (malnourished and NAT2 fast acetylators) https://t.co/fqQZC8WT7b

[Shashikant Srivastava @skant_uthct]

@iamshamminarang May her soul rest in peace. I remember you guys.

[Shashikant Srivastava @skant_uthct]

Pharmacodynamic evidence for tedizolid use in <em xmlns="https://t.co/4lU4jlxQ73">Mycobacterium avium</em> lung disease https://t.co/IAqx1yETuQ

if only the reference strain is used in PK/PD studies, it could lead to misestimates of target exposures.

[Shashikant Srivastava @skant_uthct]

Preclinical pharmacokinetics/pharmacodynamics studies defining role of ethambutol in Mycobacterium kansasii lung disease https://t.co/Qi6VUZsl0v Risk of toxicity versus no microbial kill benefit, suggests reconsidering ethambutol with respect to M. kansasii lung disease.

[Shashikant Srivastava @skant_uthct]

https://t.co/eP9flTVJVB
It was an honor to work with this team of experts led by Rie. Achieving sustainable control of Buruli ulcer requires a multifaceted approach, combining scientific advances, public health interventions, and community engagement

[Shashikant Srivastava @skant_uthct]

Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease | Microbiology Spectrum https://t.co/BRjtEG1Dgb
Optimal doses for M. abscessus pulmonary disease may not be tolerated by patients.

[Shashikant Srivastava @skant_uthct]

@nerdylilpeach It worked. Thanks for sharing.

[Shashikant Srivastava @skant_uthct]

@ShivAroor Can you post the link to the article? Thanks.

[Shashikant Srivastava @skant_uthct]

Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease https://t.co/VOKK1oEoNf

We propose to test a novel combination of epetraborole+omadacycline+β-lactam versus a standard regimen in HFS-MAB, followed by clinical trials

[Shashikant Srivastava @skant_uthct]

@GemsOfCricket Wow, this reminded me our school days.

[Shashikant Srivastava @skant_uthct]

Negative results are as important as positive ones.

Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy https://t.co/1Z4TSvINFx

[Shashikant Srivastava @skant_uthct]

Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease https://t.co/9XdI7gdOX7

[Shashikant Srivastava @skant_uthct]

@smitaprakash Nope

[Shashikant Srivastava @skant_uthct]

It's official, from Associate Professor to Professor.

I am especially grateful to all those, including many whose names I may never know, who contributed to my journey and supported my application.

[Shashikant Srivastava @skant_uthct]

@DGlaucomflecken A minor correction. ….. continue to deal with this for some time……